Noticias de CLLS_US
Noticias del mercado
Últimas noticias sobre CLLS_US — 156 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Cellectis wins FDA RMAT status for leukemia CAR-T candidate lasme-cel; shares rise
Cellectis wins FDA RMAT status for leukemia CAR-T candidate lasme-cel; shares rise
Cellectis anunció una tasa de respuesta del 100% en pacientes con leucemia objetivo para lasme-cel junto con datos positivos de linfoma para eti-cel. Se esperan lecturas...
Cellectis Unveils Strong Early CAR-T Data for Lasme-cel and Eti-cel at EHA 2026
Cellectis (NASDAQ: CLLS) unveils lasme-cel and eti-cel Phase 1 data at EHA 2026
Cellectis unveils Phase 1 clinical data
Cellectis (CLLS) 10K Form and Latest SEC Filings 2026
Vea los precios de cotización de acciones de Cellectis S.A. patrocinadas por ADR CLLS, información financiera, pronósticos en tiempo real y noticias de la compañía de CNN.
Cellectis CAR-T trials show responses in heavily pretreated blood cancers
Cellectis stock rises on FDA therapy designation By Investing.com
Cellectis stock rises on FDA therapy designation
Cellectis stock rises on FDA therapy designation By Investing.com
Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise
Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise
Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy
Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
Cellectis Says US FDA Granted RMAT Designation to Lasme-cel to Treat r/r B-ALL Patients
FDA grants RMAT to Cellectis (NASDAQ: CLLS) allogeneic CAR-T for r/r B-ALL
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
Página 1 de 8
